Physician profile
Bernie M Simons
NPI 1174548499
$14,581.41
in general payments reported to CMS, 2019-2025
53 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,907 · 2020: $1,232 · 2021: $3,847 · 2022: $4,193 · 2023: $2,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,232.81 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,866.04 | 2019-2023 | Ubrelvy, Linzess, Vraylar |
| Glaxosmithkline, LLC. | $1,295.27 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $1,056.37 | 2019-2023 | |
| Amgen INC. | $910.03 | 2019-2023 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $880.15 | 2019-2023 | Synjardy, Jardiance, Spiriva Respimat |
| Lilly USA, LLC | $800.26 | 2019-2023 | Mounjaro, Emgality, Reyvow |
| Janssen Pharmaceuticals, INC | $516.25 | 2019-2023 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $476.05 | 2019-2023 | Farxiga, Breztri, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $414.79 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $399.04 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.79 | 2019-2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $319.97 | 2019-2023 | Verquvo, Belsomra |
| Amarin Pharma, INC. | $314.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $226.19 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernie Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.